NCT02109016 - A Study to Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic Alterations | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

April 1, 2016

Study Completion Date

September 30, 2016

Conditions

Non-Small Cell Lung CancerSquamous Non-Small Cell Lung CancerNSCLCSmall Cell Lung CancerSCLCLung CancerAdvanced Lung CancerMetastatic Lung CancerStage IV Lung Cancer

Interventions

DRUG

Lucitanib

"Lucitanib given orally to all patients, once daily (q.d.), on a continuous schedule over 28-day cycles, in fasting conditions (at least 2 hours prior to and 2 hours after any meal), until progressive disease or unacceptable toxicity.~Starting dose is 10 mg/day and can be reduced in 2.5 mg decrements to 5 mg/day based on individual tolerability."

Trial Locations (19)

8035

Hospital Universitari Vall d'Hebrón, Barcelona

10043

AOU San Luigi Gonzaga, Orbassano

13915

Hôpital Nord, Marseille

14033

CHU Caen, Hôpital de la Côte de Nacre, Caen

15232

University of Pittsburgh Medical Center, Pittsburgh

20007

Georgetown University, Washington D.C.

20132

Ospedale San Raffaele, Milan

20133

Fondazione IRCCS Istituto Nazionale Tumori, Milan

20850

Associates in Oncology and Hematology, Rockville

22927

Hospital Grosshansdorf, Großhansdorf

26121

Pius Hospital Oldenburg, Oldenburg

30322

Emory University, Atlanta

37203

Tennessee Oncology, Nashville

45147

Universität Duisburg-Essen, Essen

59037

CHRU Lille, Hôpital Albert Calmette, Lille

80045

University of Colorado, Aurora

90095

University of California, Los Angeles, Los Angeles

94805

Institut Gustave-Roussy, Villejuif

06156

Ospedale S. Maria della Misericordia, Perugia